Market Overview

Qu Biologics enrolls the first patient in new Phase 2 Crohn's Disease clinical trial

Share:

VANCOUVER, British Columbia, July 25, 2018 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce that the first patient in the  RESTORE Phase 2 clinical trial for patients with moderate to severe Crohn's disease has been enrolled. The first stage of this trial is actively recruiting participants at sites in Vancouver BC, New Westminster BC and Hamilton ON.

Building on the results from Qu's initial clinical trial in Crohn's disease, the aim of this study is to further establish the safety and efficacy of the investigational drug QBECO SSI for the induction of clinical and endoscopic response and remission. QBECO SSI is intended to restore innate immune function and achieve sustained remission off all medications.

"Qu's QBECO SSI is designed to correct the innate immune suppression that underlies Crohn's disease, unlike current drugs that treat the end result of the disease by suppressing immune function," stated Dr. Hal Gunn, MD, CEO Qu Biologics. "By restoring innate immune function, we are hopeful that our novel treatment approach may achieve long-term remission or cure off medications."

Qu Biologics is recruiting a total of 20 adult Canadian residents with active moderate-to-severe Crohn's disease for the open-label stage of the RESTORE trial. Every participant will receive QBECO SSI treatment for up to 52 weeks. The results from this stage of the study will inform a subsequent 150 patient randomized controlled trial which will recruit internationally.

For information about this Crohn's disease clinical trial, visit www.restoretrial.ca and www.quibd.com.
For more information about Qu Biologics and the science behind SSIs, please visit www.qubiologics.com.

About Qu Biologics
Qu Biologics is a clinical stage biotechnology company developing Site Specific Immunomodulators (SSI), a novel class of immunotherapies designed to stimulate an innate immune response in targeted organs to reverse the chronic inflammation underlying many important diseases including inflammatory bowel disease, cancer, inflammatory lung disease and arthritis. Qu has completed three Phase 2 studies in Crohn's disease, ulcerative colitis and lung cancer.

Backed by a prestigious group of scientific advisors and board members, Qu Biologics is led by a management team that includes co-founder and CEO Dr. Hal Gunn, a physician and expert on the body's immune response to chronic disease; and Chief Medical Officer Dr. Simon Sutcliffe, former CEO of the BC Cancer Agency and a distinguished clinician, scientist and leader in cancer control in Canada and internationally.

For more information regarding this press release, contact:

Hal Gunn, MD
CEO
Qu Biologics Inc.
Phone: 604.734.1450
Email: media@qubiologics.com

Qu Biologics Inc. cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Qu Biologics' forward-looking statements due to the risks and uncertainties inherent in Qu Biologics' business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Qu Biologics does not assume any obligation to update any forward-looking statements except as required by law.

Primary Logo

View Comments and Join the Discussion!